Liquidia reports Q1 profit, sales surge 44% sequentially
Liquidia Corporation reported a 44% sequential increase in net product sales to $129.9 million for Q1 2026, marking its third consecutive profitable quarter. Net income rose to $52.9 million, and cash reserves grew to $222.8 million. The company is advancing clinical trials for L606 and new indications while targeting $1 billion in net revenue by 2027.
*this image is generated using AI for illustrative purposes only.
Liquidia Corporation reported its third consecutive quarter of profitability for the first quarter of 2026, fueled by strong demand for its Eutrepia product. The company achieved a half-billion-dollar annualized revenue run rate less than a year after launch, with management targeting at least $1 billion in net revenue by 2027. Liquidia is funding its growth initiatives, including clinical studies and manufacturing expansion, entirely through operating cash flow.
Financial Performance
Net product sales for Eutrepia reached $129.9 million in the first quarter of 2026, up from $90.1 million in the fourth quarter of 2025. This represents a 44% sequential growth in net product sales. The company reported net income of approximately $52.9 million, an increase from $14.6 million in the prior quarter. Non-GAAP adjusted EBITDA was approximately $71.2 million, up from $27.3 million in the fourth quarter of 2025.
Liquidia ended the quarter with approximately $222.8 million in cash and cash equivalents, an increase of $32.1 million from year end. The company recorded income tax expense in the first quarter and expects to continue paying taxes as profitability grows.
| Financial Metric | Q1 2026 Value | Q4 2025 Value |
|---|---|---|
| Net Product Sales | $129.9 million | $90.1 million |
| Net Income | $52.9 million | $14.6 million |
| Non-GAAP Adjusted EBITDA | $71.2 million | $27.3 million |
| Cash and Cash Equivalents | $222.8 million | N/A |
Commercial and Operational Updates
As of April 30, Liquidia received approximately 4,500 unique patient prescriptions and started approximately 3,750 patients on therapy since launch. Approximately 980 physicians have prescribed Eutrepia. The number of physicians prescribing to five or more patients grew 25% since the end of February to approximately 270.
Management noted that Eutrepia is leading the growth of the inhaled prostacycline category. The company is expanding its sales force to drive awareness in the PH-ILD and community pulmonologist sectors. Liquidia is also building new manufacturing capacity in North Carolina.
Clinical Development
Liquidia is advancing several clinical programs to expand its portfolio. The company has started recruiting for Cohort B of the ASCENT study to transition inadequate responders from Tyvaso DPI to Eutrepia. It is actively screening patients for the pivotal phase 3 RESPire study of L606, a twice-daily inhaled treprostinil suspension.
Additional clinical programs are exploring new indications for inhaled prostacyclines, including IPF, PPF, PH-COPD, and scleroderma-associated Raynaud's phenomenon. Management believes these opportunities could significantly grow the franchise value.
What risks does Liquidia face in maintaining the 44% sequential sales growth required to meet the $1 billion revenue target by 2027?
How will the expansion into community pulmonologist sectors and new indications like IPF and PH-COPD impact the company's sales and marketing expenses?
Can operating cash flow alone sustain the increased capital requirements for the new North Carolina manufacturing facility and concurrent clinical trials?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
